Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$28.23 USD
-0.04 (-0.14%)
Updated May 10, 2024 04:00 PM ET
After-Market: $28.24 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PTGX 28.23 -0.04(-0.14%)
Will PTGX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Other News for PTGX
Rani Therapeutics price target raised by $7 at BTIG, here's why
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)
Protagonist Therapeutics price target raised by $3 at JMP Securities, here's why
Protagonist Therapeutics: Q1 Earnings Snapshot